AC
SAGE

Apex Capital’s Sage Therapeutics SAGE Stock Holding History

Apex Capital’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$13.1M Sell
225,000
-125,000
-36% -$6.19M 1.4% 28
2015
Q3 		$14.8M Buy
350,000
+170,000
+94% +$10.5M 1.41% 31
2015
Q2 		$13.1M Sell
180,000
-10,000
-5% -$643K 1.14% 35
2015
Q1 		$9.54M Buy
+190,000
New +$8.17M 0.69% 49

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Apex Capital's SAGE Position: Q4 2015 in Review

Apex Capital reduced its Sage Therapeutics (SAGE) stake by 36% in Q4 2015, selling an estimated $6.19M and leaving 225,000 shares worth $13.1M. The position accounts for 1.4% of the portfolio, ranked #28.

Apex Capital first reported a position in SAGE in Q1 2015 and has held it in 4 quarters since. The position peaked at $14.8M in Q3 2015. 138 funds tracked by Wall St. Rank hold SAGE as of Q4 2015.

  • Apex Capital held 225,000 shares of Sage Therapeutics worth $13.1M as of Q4 2015.
  • Apex Capital sold 125,000 Sage Therapeutics shares in Q4 2015, an estimated $6.19M.
  • Sage Therapeutics made up 1.4% of Apex Capital's portfolio in Q4 2015, its #28 holding.
  • Apex Capital first reported a position in Sage Therapeutics in Q1 2015 and has held it in 4 quarters since.
  • Apex Capital's Sage Therapeutics position peaked at $14.8M in Q3 2015.
  • 138 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2015.

Based on Apex Capital's 13F filing for Q4 2015, filed 16 Feb 2016.